Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
暂无分享,去创建一个
Ash A. Alizadeh | R. Tibshirani | D. Botstein | G. Sherlock | P. Brown | M. Eisen | R. Levy | L. Staudt | W. C. Chan | A. Alizadeh | R. Davis | Chishieva Ma | I. Lossos | A. Rosenwald | J. Boldrick | H. Sabet | T. Tran | Xin Yu | J. Powell | Liming Yang | G. Marti | T. Moore | J. Hudson | Li-Sheng Lu | D. Lewis | W. Chan | T. Greiner | D. Weisenburger | J. Armitage | R. Warnke | W. Wilson | M. Grever | J. Byrd | D. Lewis | Jennifer C. Boldrick | Pat Brown | R. Levy | P. Brown | T. Moore | W. Wilson | D. Lewis
[1] T. Hodgkin. Excerpts from: On some morbid appearances of the absorbent glands and spleen , 1973 .
[2] S. Flexner,et al. On the Pathological Changes in Hodgkinʼs Disease, with Special Reference to its Relation to Tuberculosis , 1903 .
[3] D. M. Weir,et al. Handbook of experimental immunology , 1967 .
[4] T. Grogan,et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 , 1988 .
[5] T. Grogan,et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. , 1988, Blood.
[6] S. Jalkanen,et al. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. , 1991, The Journal of clinical investigation.
[7] D. Bahler,et al. Clonal evolution of a follicular lymphoma: evidence for antigen selection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[8] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[9] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[10] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[11] S. Bernasconi,et al. The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines. , 1994, Journal of immunology.
[12] Sa Rosenberg,et al. Classification of lymphoid neoplasms [editorial; comment] [see comments] , 1994 .
[13] Elaine S. Jaffe,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[14] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[15] Ronald W. Davis,et al. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.
[16] S. Pileri,et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. , 1995, The American journal of pathology.
[17] T. Taniguchi,et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.
[18] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[19] M. Dyer,et al. Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. , 1996, Blood.
[20] L. Staudt,et al. BCL-6 expression during B-cell activation. , 1996, Blood.
[21] J Hermans,et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Pittaluga,et al. BCL‐6 EXPRESSION IN REACTIVE LYMPHOID TISSUE AND IN B‐CELL NON‐HODGKIN'S LYMPHOMAS , 1996, The Journal of pathology.
[23] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[24] R. Kurzrock,et al. Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma , 1997, Annals of Internal Medicine.
[25] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[26] M. Hatano,et al. Disruption of the Bcl6 Gene Results in an Impaired Germinal Center Formation , 1997, The Journal of experimental medicine.
[27] B. Klein,et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.
[28] P. Pandolfi,et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.
[29] L. Staudt,et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.
[30] T. Mak,et al. Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.
[31] J. Sklar,et al. Augmented Expression of a Human Gene for 8-oxoguanine DNA Glycosylase (MutM) in B Lymphocytes of the Dark Zone in Lymph Node Germinal Centers , 1997, The Journal of experimental medicine.
[32] S. Tangye,et al. Identification of Functional Human Splenic Memory B Cells by Expression of CD148 and CD27 , 1998, The Journal of experimental medicine.
[33] J. Tschopp,et al. Inhibition of fas death signals by FLIPs. , 1998, Current opinion in immunology.
[34] Klaus Rajewsky,et al. Somatic hypermutation in normal and transformed human B cells , 1998, Immunological reviews.
[35] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[36] T. Rabbitts,et al. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. , 1998, Genes & development.
[37] J. Vose,et al. Current approaches to the management of non-Hodgkin's lymphoma. , 1998, Seminars in oncology.
[38] K. Rajewsky,et al. Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells , 1998, The Journal of experimental medicine.
[39] M. Bittner,et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.
[40] P. Biberfeld,et al. The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors , 1999, The Journal of experimental medicine.
[41] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[42] R. Offringa,et al. Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.
[43] U. Alon,et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] L. Hood,et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.
[46] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[47] E Mahlamäki,et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.
[48] P. Brown,et al. DNA arrays for analysis of gene expression. , 1999, Methods in enzymology.
[49] M. Seto,et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes , 1999, Leukemia.
[50] Ash A. Alizadeh,et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.
[51] L. Staudt,et al. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. , 1999, International reviews of immunology.
[52] 原田 信助. Molecular and immunological dissection of diffuse large B cell lymphoma : CD5[+], and CD5[-] with CD10[+] groups may constitute clinically relevant subtypes , 2000 .